Vetoquinol SA

0O1O.L

0O1O.LVetoquinol SA GB flag

London Stock Exchange

83.90

EUR

-0.90

(-1.06%)

5.32EPS

15.79P/E

992.67MMarket Cap

Sep 12Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

FR0004186856

Return %

Stock

S&P500

1.65

32.59

-38.28

31.86

30.69

96.78

Use logarithmic scale

No results.

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

No results.

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Alain Masson
Full Time Employees: 2,519
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Address: Magny-Vernois Lure France 70204
IPO Date: Mar 5, 2013
Website: vetoquinol.com
Similar Companies: Exelixis, Inc. (0IJO.L)
KOBO BIOTECH LIMITED (KOBO.BO)
Blueprint Medicines Corporation (0HOJ.L)
Bone Therapeutics SA (0R55.L)
Ji Yao Holding Group Co., Ltd. (300108.SZ)
Amicus Therapeutics, Inc. (0HF9.L)
Business: Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.